What is the price target for THRN stock?
10 analysts have analysed THRN and the average price target is 8.61 USD. This implies a price decrease of -15.52% is expected in the next year compared to the current price of 10.19.
THORNE HEALTHTECH INC (THRN) Forecast, Price Target & Analyst Ratings
NASDAQ:THRN • US8852601090
Current stock price
10.19 USD
-0.01 (-0.1%)
At close:
10.17 USD
-0.02 (-0.2%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for THORNE HEALTHTECH INC (THRN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 9, 2023
- Period
- Q3 / 2023
- EPS Estimate
- $0.06
- Revenue Estimate
- 72.944M
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.61
Upside
-15.52%
From current price of $10.19 to mean target of $8.61, Based on 10 analyst forecasts
Low
$6.06
Median
$8.16
High
$10.71
Price Target Revisions
1 Month
1.28%
3 Months
20.57%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for THRN. The average price target is 8.61 USD. This implies a price decrease of -15.52% is expected in the next year compared to the current price of 10.19.
The average price target has been revised upward by 20.57% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
THRN was analyzed by 10 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about THRN.
In the previous month the buy percentage consensus was at a similar level.
THRN was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-10-11 | Evercore ISI Group | Downgrade | Outperform -> Neutral |
| 2023-08-30 | TD Cowen | Downgrade | Outperform -> Market Perform |
| 2023-08-11 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2023-04-04 | Canaccord Genuity | Maintains | Buy |
| 2022-11-17 | Canaccord Genuity | Initiate | Buy |
| 2022-11-11 | RBC Capital | Maintains | Outperform |
| 2022-08-11 | RBC Capital | Maintains | Outperform |
| 2022-08-11 | Cowen & Co. | Maintains | Outperform |
| 2021-10-18 | RBC Capital | Initiate | Outperform |
| 2021-10-18 | Cowen & Co. | Initiate | Outperform |
| 2021-10-18 | Evercore ISI Group | Initiate | Outperform |
| 2021-10-18 | B of A Securities | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 9, 2023
- Period
- Q3 / 2023
- EPS Estimate
- $0.06
- Revenue Estimate
- 72.944M
- Revenue Q2Q
- 24.86%
- EPS Q2Q
- -12.57%
- Number of Analysts
- 4
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-0.70%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
THRN is expected to report earnings on 11/9/2023. The consensus EPS estimate for the next earnings is 0.06 USD and the consensus revenue estimate is 72.94M USD.
The next earnings revenue estimate has been revised downward by 0.7% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 138.455M 35.04% | 184.301M 33.11% | 228.731M 24.11% | 294.11M 28.58% | 368.07M 25.15% | 430.37M 16.93% | |
| EBITDA YoY % growth | 5.311M 157.06% | 15.768M 196.92% | 11.305M -28.31% | 31.316M 177.02% | 52.641M 68.10% | 76.086M 44.54% | |
| EBIT YoY % growth | 1.015M 107.30% | 11.315M 1,015.06% | 5.481M -51.56% | 23.828M 334.72% | 48.159M 102.11% | 67.024M 39.17% | |
| Operating Margin | 0.73% | 6.14% | 2.40% | 8.10% | 13.08% | 15.57% | |
| EPS YoY % growth | N/A | N/A | 0.29 64.82% | 0.33 14.31% | 0.62 87.69% | 1.08 73.77% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | |
|---|---|---|---|
| EPS Q2Q % growth | 0.06 -12.57% | 0.11 -55.38% | 0.12 1,324.00% |
| Revenue Q2Q % growth | 72.944M 24.86% | 79.199M 32.94% | 89.709M 37.51% |
| EBITDA Q2Q % growth | 7.019M -11.75% | 10.722M 17.04% | 11.618M 651.35% |
| EBIT Q2Q % growth | 5.171M 47.11% | 9.033M 170.64% | 9.904M 67,336.93% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
55.06%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
21.84%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
103.90%
EBIT Next 5 Year
N/A
THORNE HEALTHTECH INC / THRN Forecast FAQ
What is the next earnings date for THRN stock?
THORNE HEALTHTECH INC (THRN) will report earnings on 2023-11-09, after the market close.
Can you provide the consensus estimates for THORNE HEALTHTECH INC next earnings?
The consensus EPS estimate for the next earnings of THORNE HEALTHTECH INC (THRN) is 0.06 USD and the consensus revenue estimate is 72.94M USD.
Can you provide the consensus rating for THORNE HEALTHTECH INC stock?
The consensus rating for THORNE HEALTHTECH INC (THRN) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.